Objectives To explore extracorporeal membrane oxygenation (ECMO)-related alterations of
the pharmacokinetics (PK) of piperacillin/tazobactam and determine an optimal dosage …

Objectives We utilized the database of the Defining Antibiotic Levels in Intensive care unit
patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and …

Background Ceftazidime is commonly used as a key antibiotic against Pseudomonas
aeruginosa in critically ill patients. ICU patients have severely altered and variable antibiotic …

Study Objective. To compare conventional intermittent dosing regimens of piperacillin‐
tazobactam with prolonged and continuous infusions to determine the optimal dosing …

This study aimed to characterize the population pharmacokinetics (PKs) of piperacillin and
investigate probability of target attainment (PTA) and cumulative fraction of response (CFR) …

Background Altered pharmacokinetics in obese patients raise concerns over worse clinical
outcomes. This study assessed whether obese patients receiving a β-lactam have worse …

Study Objective To evaluate the pharmacokinetic and pharmacodynamic profiles of
piperacillin‐tazobactam administered as a 4‐hour infusion in critically ill patients undergoing …

Twenty-three generic intravenous piperacillin/tazobactam products were compared for in
vitro activity to the branded formulation (Zosyn®, Wyeth, Philadelphia, PA) by disk diffusion …

OBJECTIVE: To mathematically assess drug losses due to infusion line residuals and
evaluate methods to compensate for drug loss due to residual volumes in intravenous pump …

Figure 1. Probability of and time to first instance of concentrations exceeding the breakpoint
minimum inhibitory concentrations (MICs) for piperacillin–tazobactam (TZP; 16 mg/L) and …